{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T03:36:51Z","timestamp":1793417811976,"version":"4.5.0"},"reference-count":79,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T00:00:00Z","timestamp":1674604800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Mycosis fungoides and S\u00e9zary syndrome are epidermotropic cutaneous lymphomas, and both of them are rare diseases. Mycosis fungoides is the most frequent primary cutaneous lymphoma. In about 25% of patients with mycosis fungoides, the disease may progress to higher stages. The pathogenesis and risk factors of progression in mycosis fungoides and S\u00e9zary syndrome are not yet fully understood. Previous works have investigated inter- and intrapatient tumor cell heterogeneity. Here, we overview the role of the tumor microenvironment of mycosis fungoides and S\u00e9zary syndrome by describing its key components and functions. Emphasis is put on the role of the microenvironment in promoting tumor growth or antitumor immune response, as well as possible therapeutic targets. We focus on recent advances in the field and point out treatment-related alterations of the microenvironment. Deciphering the tumor microenvironment may help to develop strategies that lead to long-term disease control and cure.<\/jats:p>","DOI":"10.3390\/cancers15030746","type":"journal-article","created":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T02:29:31Z","timestamp":1674700171000},"page":"746","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Mycosis Fungoides and S\u00e9zary Syndrome: Microenvironment and Cancer Progression"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2544-7197","authenticated-orcid":false,"given":"Gabor","family":"Dobos","sequence":"first","affiliation":[{"name":"Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt, 10117 Berlin, Germany"},{"name":"Department of Dermatology, Universit\u00e4t zu Berlin, 10117 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Lazaridou","sequence":"additional","affiliation":[{"name":"Dermatology, Brown University, Providence, RI 02912, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7828-6211","authenticated-orcid":false,"given":"Ad\u00e8le","family":"de Masson","sequence":"additional","affiliation":[{"name":"Dermatology Department, Saint-Louis Hospital, AP-HP, 75010 Paris, France"},{"name":"Department of Medicine, Universit\u00e9 Paris Cit\u00e9, 75010 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"eaar5894","DOI":"10.1126\/scitranslmed.aar5894","article-title":"High-Throughput Sequencing of the T Cell Receptor \u03b2 Gene Identifies Aggressive Early-Stage Mycosis Fungoides","volume":"10","author":"Elco","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"487","DOI":"10.5021\/ad.2021.33.6.487","article-title":"The Role of Tumor Microenvironment in Mycosis Fungoides and S\u00e9zary Syndrome","volume":"33","author":"Liu","year":"2021","journal-title":"Ann. Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Pileri, A., Guglielmo, A., Grandi, V., Violetti, S.A., Fanoni, D., Fava, P., Agostinelli, C., Berti, E., Quaglino, P., and Pimpinelli, N. (2021). The Microenvironment\u2019s Role in Mycosis Fungoides and S\u00e9zary Syndrome: From Progression to Therapeutic Implications. Cells, 10.","DOI":"10.3390\/cells10102780"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.jid.2020.07.026","article-title":"Phenotypical Markers, Molecular Mutations, and Immune Microenvironment as Targets for New Treatments in Patients with Mycosis Fungoides and\/or S\u00e9zary Syndrome","volume":"141","author":"Quaglino","year":"2021","journal-title":"J. Invest. Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/CCO.0000000000000243","article-title":"Tumor Microenvironment in Mycosis Fungoides and S\u00e9zary Syndrome","volume":"28","author":"Zain","year":"2016","journal-title":"Curr. Opin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1182\/blood-2017-03-772996","article-title":"Circulating and Skin-Derived S\u00e9zary Cells: Clonal but with Phenotypic Plasticity","volume":"130","author":"Roelens","year":"2017","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"4443","DOI":"10.1158\/1078-0432.CCR-19-0148","article-title":"Single-Cell Lymphocyte Heterogeneity in Advanced Cutaneous T-Cell Lymphoma Skin Tumors","volume":"25","author":"Gaydosik","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1158\/1078-0432.CCR-12-3488","article-title":"TH2 Cytokines from Malignant Cells Suppress TH1 Responses and Enforce a Global TH2 Bias in Leukemic Cutaneous T-Cell Lymphoma","volume":"19","author":"Guenova","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1182\/blood-2002-11-3574","article-title":"Mycosis Fungoides Shows Concurrent Deregulation of Multiple Genes Involved in the TNF Signaling Pathway: An Expression Profile Study","volume":"102","author":"Tracey","year":"2003","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"198","DOI":"10.3389\/fonc.2018.00198","article-title":"New Therapies and Immunological Findings in Cutaneous T-Cell Lymphoma","volume":"8","author":"Fujii","year":"2018","journal-title":"Front. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s00281-016-0594-9","article-title":"Malignant Inflammation in Cutaneous T-cell Lymphoma\u2014A Hostile Takeover","volume":"39","author":"Krejsgaard","year":"2017","journal-title":"Semin. Immunopathol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"851","DOI":"10.3389\/fcell.2020.00851","article-title":"Cellular Interactions and Inflammation in the Pathogenesis of Cutaneous T-Cell Lymphoma","volume":"8","author":"Stolearenco","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1111\/jdv.12299","article-title":"Genetic Markers Associated with Progression in Early Mycosis Fungoides","volume":"28","author":"Johnson","year":"2014","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"9717530","DOI":"10.1155\/2016\/9717530","article-title":"S\u00e9zary Syndrome and Atopic Dermatitis: Comparison of Immunological Aspects and Targets","volume":"2016","author":"Saulite","year":"2016","journal-title":"BioMed Res. Int."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"131","DOI":"10.12788\/cutis.0066","article-title":"Cutaneous T-Cell Lymphoma and Concomitant Atopic Dermatitis Responding to Dupilumab","volume":"106","author":"Mollanazar","year":"2020","journal-title":"Cutis"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"adv00271","DOI":"10.2340\/00015555-3576","article-title":"Dupilumab Treatment in Two Patients with Cutaneous T-Cell Lymphomas","volume":"100","author":"Lazaridou","year":"2020","journal-title":"Acta Derm. Venereol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Park, A., Wong, L., Lang, A., Kraus, C., Anderson, N., and Elsensohn, A. (2022). Cutaneous T-cell Lymphoma Following Dupilumab Use: A Systematic Review. Int. J. Dermatol., ijd.16388.","DOI":"10.1111\/ijd.16388"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.it.2013.10.001","article-title":"Tolerance and Exhaustion: Defining Mechanisms of T Cell Dysfunction","volume":"35","author":"Schietinger","year":"2014","journal-title":"Trends Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1158\/2326-6066.CIR-17-0270","article-title":"Primary T Cells from Cutaneous T-Cell Lymphoma Skin Explants Display an Exhausted Immune Checkpoint Profile","volume":"6","author":"Querfeld","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40425-018-0316-z","article-title":"Development of PD-1 and PD-L1 Inhibitors as a Form of Cancer Immunotherapy: A Comprehensive Review of Registration Trials and Future Considerations","volume":"6","author":"Gong","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"328rv4","DOI":"10.1126\/scitranslmed.aad7118","article-title":"PD-L1 (B7-H1) and PD-1 Pathway Blockade for Cancer Therapy: Mechanisms, Response Biomarkers, and Combinations","volume":"8","author":"Zou","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12943-018-0928-4","article-title":"Role of the Tumor Microenvironment in PD-L1\/PD-1-Mediated Tumor Immune Escape","volume":"18","author":"Jiang","year":"2019","journal-title":"Mol. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1001\/archdermatol.2010.200","article-title":"Increased Programmed Death-1 Expression on CD4+ T Cells in Cutaneous T-Cell Lymphoma: Implications for Immune Suppression","volume":"146","author":"Samimi","year":"2010","journal-title":"Arch. Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1001\/archdermatol.2012.2089","article-title":"Differential Expression of Programmed Death-1 (PD-1) in S\u00e9zary Syndrome and Mycosis Fungoides","volume":"148","author":"Jansen","year":"2012","journal-title":"Arch. Dermatol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Seliger, B. (2019). Basis of PD1\/PD-L1 Therapies. J. Clin. Med., 8.","DOI":"10.3390\/jcm8122168"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/DAD.0b013e31821c35cb","article-title":"Expression Patterns of the Immunosuppressive Proteins PD-1\/CD279 and PD-L1\/CD274 at Different Stages of Cutaneous T-Cell Lymphoma\/Mycosis Fungoides","volume":"34","author":"Kantekure","year":"2012","journal-title":"Am. J. Dermatopathol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/bjd.21063","article-title":"Expression of Immune Checkpoint Molecules Programmed Death Protein 1, Programmed Death-Ligand 1 and Inducible T-Cell Co-Stimulator in Mycosis Fungoides and S\u00e9zary Syndrome: Association with Disease Stage and Clinical Outcome","volume":"187","author":"Palmer","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/DAD.0b013e3182a72f8c","article-title":"Expression of Follicular Helper T-Cell Markers in Primary Cutaneous T-Cell Lymphoma","volume":"36","author":"Park","year":"2014","journal-title":"Am. J. Dermatopathol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1200\/JCO.19.01056","article-title":"Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and S\u00e9zary Syndrome: A Multicenter Phase II Study","volume":"38","author":"Khodadoust","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in Patients with Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/S0959-8049(21)00668-7","article-title":"Phase II Trial of Atezolizumab (Anti-PD-L1) in the Treatment of Stage IIb-IVB Mycosis Fungoides\/S\u00e9zary Syndrome Patients Relapsed\/Refractory after a Previous Systemic Treatment (PARCT)","volume":"156","author":"Stadler","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/blood-2020-143354","article-title":"Phase 1 Results of Anti-PD-Ligand 1 (Durvalumab) & Lenalidomide in Patients with Cutaneous T Cell Lymphoma and Correlation with Programmed Death Ligand 1 Expression and Gene Expression Profile","volume":"136","author":"Querfeld","year":"2020","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"6726","DOI":"10.1038\/s41467-021-26974-6","article-title":"Immune Cell Topography Predicts Response to PD-1 Blockade in Cutaneous T Cell Lymphoma","volume":"12","author":"Phillips","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Kim, J.Y., Lee, K.H., Kang, J., Borcoman, E., Saada-Bouzid, E., Kronbichler, A., Hong, S.H., de Rezende, L.F.M., Ogino, S., and Keum, N. (2019). Hyperprogressive Disease during Anti-PD-1 (PDCD1)\/PD-L1 (CD274) Therapy: A Systematic Review and Meta-Analysis. Cancers, 11.","DOI":"10.3390\/cancers11111699"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Gao, Y., Hu, S., Li, R., Jin, S., Liu, F., Liu, X., Li, Y., Yan, Y., Liu, W., and Gong, J. (2023). Hyperprogression of Cutaneous T Cell Lymphoma after Anti-PD-1 Treatment. JCI Insight, e164793.","DOI":"10.1172\/jci.insight.164793"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"5066","DOI":"10.1038\/s41467-020-18828-4","article-title":"Structural Characterization of the ICOS\/ICOS-L Immune Complex Reveals High Molecular Mimicry by Therapeutic Antibodies","volume":"11","author":"Rujas","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e000544","DOI":"10.1136\/esmoopen-2019-000544","article-title":"The Rationale behind Targeting the ICOS-ICOS Ligand Costimulatory Pathway in Cancer Immunotherapy","volume":"5","author":"Solinas","year":"2020","journal-title":"ESMO Open"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"687673","DOI":"10.3389\/fimmu.2021.687673","article-title":"Highly Multiplexed Phenotyping of Immunoregulatory Proteins in the Tumor Microenvironment by CODEX Tissue Imaging","volume":"12","author":"Phillips","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00262-017-2090-z","article-title":"Therapeutic Reduction of Cell-Mediated Immunosuppression in Mycosis Fungoides and S\u00e9zary Syndrome","volume":"67","author":"Geskin","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1182\/bloodadvances.2020002395","article-title":"ICOS Is Widely Expressed in Cutaneous T-Cell Lymphoma, and Its Targeting Promotes Potent Killing of Malignant Cells","volume":"4","author":"Amatore","year":"2020","journal-title":"Blood Adv."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1182\/blood-2020-136465","article-title":"A Phase I Study of Anti-ICOS Antibody MEDI-570 for Relapsed\/Refractory (R\/R) Peripheral T-Cell Lymphoma (PTCL) and Angioimmunoblastic T-Cell Lymphoma (AITL) (NCI-9930)","volume":"136","author":"Chavez","year":"2020","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/imr.12518","article-title":"TIGIT and CD96: New Checkpoint Receptor Targets for Cancer Immunotherapy","volume":"276","author":"Dougall","year":"2017","journal-title":"Immunol. Rev."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e1036214","DOI":"10.1080\/2162402X.2015.1036214","article-title":"The Checkpoint Inhibitor TIGIT Limits Antitumor and Antiviral CD8+ T Cell Responses","volume":"4","author":"Johnston","year":"2015","journal-title":"OncoImmunology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/s41590-018-0132-0","article-title":"Blockade of the Checkpoint Receptor TIGIT Prevents NK Cell Exhaustion and Elicits Potent Anti-Tumor Immunity","volume":"19","author":"Zhang","year":"2018","journal-title":"Nat. Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1080\/10428194.2018.1564827","article-title":"Divergent LAG-3 versus BTLA, TIGIT, and FCRL3 Expression in S\u00e9zary Syndrome","volume":"60","author":"Anzengruber","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1158\/1535-7163.MCT-20-0464","article-title":"Restoration of T-Cell Effector Function, Depletion of Tregs, and Direct Killing of Tumor Cells: The Multiple Mechanisms of Action of a-TIGIT Antagonist Antibodies","volume":"20","author":"Preillon","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1470-2045(22)00226-1","article-title":"Tiragolumab plus Atezolizumab versus Placebo plus Atezolizumab as a First-Line Treatment for PD-L1-Selected Non-Small-Cell Lung Cancer (CITYSCAPE): Primary and Follow-up Analyses of a Randomised, Double-Blind, Phase 2 Study","volume":"23","author":"Cho","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.4049\/jimmunol.178.6.3358","article-title":"Cutting Edge: Chemokine Receptor CCR4 Is Necessary for Antigen-Driven Cutaneous Accumulation of CD4 T Cells under Physiological Conditions","volume":"178","author":"Campbell","year":"2007","journal-title":"J. Immunol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"809","DOI":"10.2340\/00015555-3207","article-title":"Expression of CCR3 and CCR4 Suggests a Poor Prognosis in Mycosis Fungoides and S\u00e9zary Syndrome","volume":"99","author":"Shono","year":"2019","journal-title":"Acta Derm. Venereol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus Vorinostat in Previously Treated Cutaneous T-Cell Lymphoma (MAVORIC): An International, Open-Label, Randomised, Controlled Phase 3 Trial","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1182\/blood.2021013341","article-title":"Macrophage-Derived CXCL9 and CXCL11, T-Cell Skin Homing, and Disease Control in Mogamulizumab-Treated CTCL Patients","volume":"139","author":"Darbord","year":"2022","journal-title":"Blood"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3732","DOI":"10.1182\/blood.2021014468","article-title":"Resistance to Mogamulizumab Is Associated with Loss of CCR4 in Cutaneous T-Cell Lymphoma","volume":"139","author":"Beygi","year":"2022","journal-title":"Blood"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1111\/bjd.21018","article-title":"Mogamulizumab Induces Long-Term Immune Restoration and Reshapes Tumour Heterogeneity in S\u00e9zary Syndrome","volume":"186","author":"Roelens","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"117ra7","DOI":"10.1126\/scitranslmed.3003008","article-title":"Skin Effector Memory T Cells Do Not Recirculate and Provide Immune Protection in Alemtuzumab-Treated CTCL Patients","volume":"4","author":"Clark","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1158\/0008-5472.CAN-20-3585","article-title":"Fc-Optimized Anti-CCR8 Antibody Depletes Regulatory T Cells in Human Tumor Models","volume":"81","author":"Campbell","year":"2021","journal-title":"Cancer Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e001749","DOI":"10.1136\/jitc-2020-001749","article-title":"Therapeutic Depletion of CCR8+ Tumor-Infiltrating Regulatory T Cells Elicits Antitumor Immunity and Synergizes with Anti-PD-1 Therapy","volume":"9","author":"Dombrecht","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1182\/bloodadvances.2021006512","article-title":"CCR8 Is a New Therapeutic Target in Cutaneous T-Cell Lymphomas","volume":"6","author":"Giustiniani","year":"2022","journal-title":"Blood Adv."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Jost, M., and Wehkamp, U. (2022). The Skin Microbiome and Influencing Elements in Cutaneous T-Cell Lymphomas. Cancers, 14.","DOI":"10.3390\/cancers14051324"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"7529","DOI":"10.1158\/1078-0432.CCR-11-1192","article-title":"IL-22, but Not IL-17, Dominant Environment in Cutaneous T-Cell Lymphoma","volume":"17","author":"Miyagaki","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/imr.12558","article-title":"IL-25 in Allergic Inflammation","volume":"278","author":"Xu","year":"2017","journal-title":"Immunol. Rev."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1111\/bjd.16237","article-title":"Interleukin-25 Is Involved in Cutaneous T-Cell Lymphoma Progression by Establishing a T Helper 2-Dominant Microenvironment","volume":"178","author":"Nakajima","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"6241","DOI":"10.1158\/0008-5472.CAN-16-0992","article-title":"Thymic Stromal Chemokine TSLP Acts through Th2 Cytokine Production to Induce Cutaneous T-Cell Lymphoma","volume":"76","author":"Takahashi","year":"2016","journal-title":"Cancer Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.jid.2020.06.034","article-title":"Cancer-Associated Fibroblasts in Mycosis Fungoides Promote Tumor Cell Migration and Drug Resistance through CXCL12\/CXCR4","volume":"141","author":"Aronovich","year":"2021","journal-title":"J. Invest. Dermatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.jaci.2020.01.042","article-title":"Single-Cell Transcriptome Analysis of Human Skin Identifies Novel Fibroblast Subpopulation and Enrichment of Immune Subsets in Atopic Dermatitis","volume":"145","author":"He","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e124233","DOI":"10.1172\/jci.insight.124233","article-title":"Benign T Cells Drive Clinical Skin Inflammation in Cutaneous T Cell Lymphoma","volume":"4","author":"Crouch","year":"2019","journal-title":"JCI Insight"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0959-8049(21)00631-6","article-title":"Exploring the Role of the Skin Microenvironment in Cutaneous T-Cell Lymphoma Using Single Cell RNA-Sequencing","volume":"156","author":"Dobos","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"4575","DOI":"10.21873\/anticanres.11006","article-title":"Expression of CD31 in Mycosis Fungoides","volume":"36","author":"Kobierzycki","year":"2016","journal-title":"Anticancer Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2340\/00015555-2517","article-title":"Podoplanin Expression Correlates with Disease Progression in Mycosis Fungoides","volume":"97","author":"Kobierzycki","year":"2017","journal-title":"Acta Derm. Venereol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"819","DOI":"10.3109\/10428194.2012.726720","article-title":"Vascular Endothelial Growth Factor Receptor-3 Expression in Mycosis Fungoides","volume":"54","author":"Pedersen","year":"2013","journal-title":"Leuk. Lymphoma"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/1346-8138.14033","article-title":"Serum Vascular Endothelial Growth Factor A Levels Reflect Itch Severity in Mycosis Fungoides and S\u00e9zary Syndrome","volume":"45","author":"Sakamoto","year":"2018","journal-title":"J. Dermatol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/DAD.0b013e3181b72678","article-title":"Immunohistochemical Study of the Expression of Matrix Metalloproteinase-9 in Skin Lesions of Mycosis Fungoides","volume":"32","author":"Rasheed","year":"2010","journal-title":"Am. J. Dermatopathol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jdermsci.2012.07.007","article-title":"Association of the Numbers of CD163+ Cells in Lesional Skin and Serum Levels of Soluble CD163 with Disease Progression of Cutaneous T Cell Lymphoma","volume":"68","author":"Sugaya","year":"2012","journal-title":"J. Dermatol. Sci."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/exd.12873","article-title":"The Possible Interaction between Periostin Expressed by Cancer Stroma and Tumor-Associated Macrophages in Developing Mycosis Fungoides","volume":"25","author":"Furudate","year":"2016","journal-title":"Exp. Dermatol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/exd.12894","article-title":"Mac Attack: Macrophages as Key Drivers of Cutaneous T-Cell Lymphoma Pathogenesis","volume":"25","author":"Assaf","year":"2016","journal-title":"Exp. Dermatol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/CCO.0000000000000468","article-title":"Targeting CD47 as a Cancer Therapeutic Strategy: The Cutaneous T-Cell Lymphoma Experience","volume":"30","author":"Folkes","year":"2018","journal-title":"Curr. Opin. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1182\/blood.2021013901","article-title":"Targeting Macrophages for Enhancing CD47 Blockade\u2013Elicited Lymphoma Clearance and Overcoming Tumor-Induced Immunosuppression","volume":"139","author":"Cao","year":"2022","journal-title":"Blood"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1600-0560.1979.tb01159.x","article-title":"Target Role of Langerhans Cells in Mycosis Fungoides: Transmission and Immuno-Electron Microscopic Studies","volume":"6","author":"Rowden","year":"1979","journal-title":"J. Cutan. Pathol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1182\/blood-2012-03-415638","article-title":"Mast Cells Play a Protumorigenic Role in Primary Cutaneous Lymphoma","volume":"120","author":"Rabenhorst","year":"2012","journal-title":"Blood"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Eder, J., Rogojanu, R., Jerney, W., Erhart, F., Dohnal, A., Kitzw\u00f6gerer, M., Steiner, G., Moser, J., and Trautinger, F. (2016). Mast Cells Are Abundant in Primary Cutaneous T-Cell Lymphomas: Results from a Computer-Aided Quantitative Immunohistological Study. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0163661"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/3\/746\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:15:40Z","timestamp":1760120140000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/3\/746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,25]]},"references-count":79,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["cancers15030746"],"URL":"https:\/\/doi.org\/10.3390\/cancers15030746","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,25]]}}}